Trial · NCT03006341
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Obesity | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| PRIMARY | Percentage of Patients Smoking | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| PRIMARY | Percentage of Patients With Alcohol Consumption | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| PRIMARY | Percentage of Patients With Abnormal Renal Function | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| PRIMARY | Percentage of Patients With Bleeding History or Predisposition | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| PRIMARY | EMR Characteristic: Renal Function - Glomerular Filtration Rate (GFR) | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Milliliter/minute/1.73 square meter | MEAN |
| PRIMARY | EMR Characteristic: Serum Creatinine | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Milligrams per deciliter | MEAN |
| PRIMARY | Percentage of Patients With Abnormal Liver Function | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| SECONDARY | EMR Characteristic: Duration of Atrial Fibrillation | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. Duration calculated for patients identified as having condition in EMR. | Months | MEAN |
| SECONDARY | EMR Characteristic: History of Adherence: Non-adherent/Adherent | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. Although the original intent was to document the patient's history of adherence, no such information was available in the EMR | ||
| SECONDARY | EMR Characteristic: History/Duration of Hypertension | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Months | MEAN |
| SECONDARY | Percentage of Patients With Uncontrolled Hypertension | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| SECONDARY | EMR Characteristic: History/Duration of Congestive Heart Failure (CHF) | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Months | MEAN |
| SECONDARY | Percentage of Patients With Prior Transient Ischemic Attack | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| SECONDARY | Percentage of Patients With Diabetes | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| SECONDARY | Percentage of Patients With Hyperlipidemia | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
| SECONDARY | EMR Characteristic: Hypertension, Abnormal Liver/Renal Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol Usage (HAS-BLED) Score | Up to 12 months | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. Also the patients with data for all HAS-BLED components. | Unit on Scale | MEAN |
| SECONDARY | Percentage of Patients With Use of Antiplatelets or Non-steroidal Anti-inflammatory Drugs | Up to 1 month | Two sets of results are provided, before and after PS matching. Rivaroxaban and Apixaban correspond to post-hoc analyses not pre-specified in the protocol and hence not included in the outcome measures. | Percentage of patients | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03006341/outcomes